Cyclosporin A and imipenem associated seizure activity in allogeneic bone marrow transplantation patients.
Imipenem is an antibiotic used with cilastatin in the bone marrow transplant (BMT) setting. Cyclosporin A (CsA) is an immunosuppressive agent. Seizures can be seen with both imipenem/cilastatin and CsA. Our hypothesis for study was that CNS toxicity and seizures are increased by the concomitant administration of CsA and imipenem/cilastatin. Between December of 1989 and 1996, all of the 166 stem cell BMTs performed at Mount Sinai Hospital in New York were evaluated for this study. Three groups were studied: 77 patients received CsA alone (Group 1); 89 patients received imipenem/cilastatin, and of these, 45 received concomitant CsA (Group 2); and 44 patients who underwent autologous BMT received imipenem/cilastatin only (Group 3). We observed a total of 5 seizure episodes. There were no statistical differences in frequency between the groups. Adverse effects may be difficult to relate to a particular drug, especially for patients on multidrug regimens but the use of imipenem/cilastatin and CsA did not cause a significant rise in the frequency of seizures when compared to CsA alone.
Turhal
N S
NS
Marmara University, Department of Internal Medicine, Division of Oncology, Istanbul, Turkey. turhal@superonline.com
D000328:Adult; D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015378:Imipenem / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000139:chemically induced*; D012640:Seizures / Q000139:chemically induced*
D007166:Immunosuppressive Agents; D015378:Imipenem; D016572:Cyclosporine